ganciclovir ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals bicyclic heterocycle compounds 1277 82410-32-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ganciclovir
  • denosine
  • gancyclovir
  • hydroxyacyclovir
  • natclovir
  • ganciclovir sodium
An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.
  • Molecular weight: 255.23
  • Formula: C9H13N5O4
  • CLOGP: -2.15
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 4
  • TPSA: 134.99
  • ALOGS: -1.35
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 g O
0.50 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 6 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 91 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 78.36 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 4 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.99 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 23, 1989 FDA ROCHE PALO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection 1122.87 23.38 325 10984 18971 56261787
Drug resistance 426.76 23.38 159 11150 20383 56260375
Cytomegalovirus viraemia 405.51 23.38 110 11199 5010 56275748
Post transplant lymphoproliferative disorder 317.41 23.38 89 11220 4583 56276175
Epstein-Barr virus infection 313.55 23.38 98 11211 7365 56273393
Pathogen resistance 295.41 23.38 89 11220 5911 56274847
Smooth muscle cell neoplasm 271.54 23.38 56 11253 752 56280006
Encephalitis cytomegalovirus 230.66 23.38 46 11263 516 56280242
Multiple organ dysfunction syndrome 224.89 23.38 137 11172 52633 56228125
Cytomegalovirus chorioretinitis 189.88 23.38 48 11261 1650 56279108
Cytomegalovirus infection reactivation 177.59 23.38 52 11257 3124 56277634
Graft versus host disease 157.33 23.38 57 11252 6724 56274034
Off label use 153.57 23.38 341 10968 555839 55724919
Pneumonia cytomegaloviral 148.83 23.38 41 11268 1973 56278785
Cytomegalovirus test positive 148.06 23.38 44 11265 2782 56277976
Cytomegalovirus colitis 147.10 23.38 41 11268 2061 56278697
Pancytopenia 144.71 23.38 129 11180 88586 56192172
Nephropathy toxic 134.17 23.38 54 11255 8473 56272285
Neutropenia 121.49 23.38 154 11155 158013 56122745
Leukopenia 121.32 23.38 106 11203 70834 56209924
Cystitis haemorrhagic 117.80 23.38 40 11269 3897 56276861
Transplant rejection 109.93 23.38 49 11260 9885 56270873
Fatigue 108.98 23.38 15 11294 788537 55492221
Haemophagocytic lymphohistiocytosis 108.45 23.38 48 11261 9524 56271234
Acute graft versus host disease 96.48 23.38 35 11274 4140 56276618
Pain 90.62 23.38 13 11296 663171 55617587
Haemorrhage intracranial 86.60 23.38 45 11264 12710 56268048
Product use in unapproved indication 86.46 23.38 123 11186 140699 56140059
Epstein-Barr virus associated lymphoproliferative disorder 85.51 23.38 26 11283 1777 56278981
Cytomegalovirus gastrointestinal infection 78.77 23.38 17 11292 287 56280471
Pneumocystis jirovecii pneumonia 77.84 23.38 45 11264 15656 56265102
Cytomegalovirus enterocolitis 76.75 23.38 19 11290 598 56280160
Sepsis 74.10 23.38 114 11195 139726 56141032
Renal impairment 73.91 23.38 86 11223 80627 56200131
Septic shock 73.47 23.38 75 11234 60760 56219998
Transplant dysfunction 71.02 23.38 29 11280 4717 56276041
Bronchopulmonary aspergillosis 70.37 23.38 34 11275 8230 56272528
Acute graft versus host disease in skin 67.17 23.38 25 11284 3177 56277581
Renal failure 67.01 23.38 96 11213 110404 56170354
Thrombotic microangiopathy 66.18 23.38 34 11275 9377 56271381
Adenovirus infection 65.65 23.38 25 11284 3383 56277375
Bone marrow failure 64.50 23.38 50 11259 28236 56252522
Aspergillus infection 64.43 23.38 31 11278 7434 56273324
Arthralgia 63.60 23.38 12 11297 501657 55779101
Graft versus host disease in gastrointestinal tract 61.85 23.38 23 11286 2916 56277842
Respiratory failure 58.23 23.38 83 11226 94979 56185779
Kidney transplant rejection 57.15 23.38 24 11285 4189 56276569
Dyspnoea 55.43 23.38 25 11284 592552 55688206
Cytomegalovirus oesophagitis 54.56 23.38 12 11297 222 56280536
Graft versus host disease in skin 52.66 23.38 20 11289 2687 56278071
Epstein-Barr virus infection reactivation 51.46 23.38 14 11295 642 56280116
Posterior reversible encephalopathy syndrome 49.53 23.38 34 11275 15926 56264832
Alopecia 47.16 23.38 3 11306 293455 55987303
BK virus infection 46.79 23.38 19 11290 3045 56277713
Nausea 46.79 23.38 51 11258 764127 55516631
Mucormycosis 45.12 23.38 18 11291 2756 56278002
Parvovirus B19 infection 44.81 23.38 12 11297 518 56280240
Viral haemorrhagic cystitis 44.36 23.38 13 11296 782 56279976
Ureaplasma infection 44.30 23.38 12 11297 541 56280217
Abdominal discomfort 44.06 23.38 3 11306 277271 56003487
Gastric ulcer 43.18 23.38 36 11273 22527 56258231
Chronic graft versus host disease 42.33 23.38 18 11291 3238 56277520
Epstein-Barr viraemia 41.97 23.38 13 11296 945 56279813
Headache 41.70 23.38 31 11278 559013 55721745
Thrombocytopenia 41.15 23.38 87 11222 136137 56144621
Agranulocytosis 40.98 23.38 35 11274 22624 56258134
Hepatic function abnormal 40.60 23.38 42 11267 34516 56246242
Cytomegalovirus gastritis 40.21 23.38 9 11300 181 56280577
Lung transplant rejection 40.10 23.38 12 11297 776 56279982
Pyrexia 38.42 23.38 176 11133 418597 55862161
Myelosuppression 37.93 23.38 30 11279 17425 56263333
Pulmonary haemorrhage 37.82 23.38 21 11288 6762 56273996
Swelling 36.93 23.38 3 11306 239768 56040990
Product use issue 35.97 23.38 100 11209 185941 56094817
Immune reconstitution inflammatory syndrome 35.61 23.38 19 11290 5655 56275103
Human herpesvirus 6 infection 35.45 23.38 15 11294 2667 56278091
Hyperammonaemia 35.17 23.38 18 11291 4922 56275836
Polyomavirus-associated nephropathy 34.83 23.38 13 11296 1664 56279094
Disseminated cytomegaloviral infection 34.28 23.38 8 11301 195 56280563
Complications of transplanted kidney 34.06 23.38 14 11295 2315 56278443
Enterococcal infection 34.04 23.38 20 11289 7164 56273594
Brain oedema 33.64 23.38 25 11284 13246 56267512
Intentional product use issue 32.81 23.38 66 11243 99667 56181091
Hyperlactacidaemia 32.63 23.38 14 11295 2574 56278184
Pseudomonas infection 32.54 23.38 22 11287 10049 56270709
Transplant failure 32.45 23.38 12 11297 1497 56279261
Hydrocephalus 32.14 23.38 17 11292 4972 56275786
Acute respiratory distress syndrome 31.99 23.38 30 11279 21896 56258862
Dizziness 31.89 23.38 18 11291 376122 55904636
Aplasia pure red cell 31.43 23.38 16 11293 4326 56276432
Hypogammaglobulinaemia 30.73 23.38 18 11291 6408 56274350
Hypersensitivity 30.63 23.38 7 11302 256401 56024357
Pain in extremity 30.24 23.38 11 11298 297420 55983338
Liver transplant rejection 30.09 23.38 11 11298 1329 56279429
Pruritus 30.08 23.38 13 11296 316610 55964148
Drug hypersensitivity 30.05 23.38 9 11300 275196 56005562
Cytomegalovirus nephritis 29.73 23.38 5 11304 19 56280739
Leukoencephalopathy 29.43 23.38 15 11294 4067 56276691
Renal transplant failure 28.60 23.38 9 11300 689 56280069
Venoocclusive liver disease 28.30 23.38 15 11294 4406 56276352
Cytomegalovirus enteritis 27.70 23.38 7 11302 240 56280518
Fall 27.68 23.38 19 11290 357491 55923267
Bacterial sepsis 27.68 23.38 14 11295 3735 56277023
Klebsiella infection 27.61 23.38 18 11291 7738 56273020
Acute graft versus host disease in intestine 27.48 23.38 11 11298 1699 56279059
Hyphaema 27.34 23.38 7 11302 253 56280505
Malaise 26.60 23.38 21 11288 367839 55912919
Immunosuppressant drug level increased 26.54 23.38 13 11296 3240 56277518
Confabulation 26.25 23.38 7 11302 297 56280461
Central nervous system necrosis 26.25 23.38 6 11303 133 56280625
Encephalitis Japanese B 25.96 23.38 5 11304 46 56280712
Ataxia 25.54 23.38 22 11287 14381 56266377
Back pain 25.44 23.38 8 11301 237162 56043596
Colitis 24.83 23.38 36 11273 41775 56238983
Incision site pain 24.79 23.38 9 11300 1066 56279692
Red blood cells urine positive 24.67 23.38 12 11297 2944 56277814
Renal tubular necrosis 24.37 23.38 19 11290 10809 56269949
Necrotising retinitis 24.22 23.38 7 11302 401 56280357
Weight increased 24.19 23.38 8 11301 229695 56051063
Systemic mycosis 24.14 23.38 9 11300 1148 56279610
Apraxia 24.01 23.38 10 11299 1709 56279049
Disseminated cryptococcosis 23.92 23.38 7 11302 419 56280339
Strongyloidiasis 23.74 23.38 9 11300 1202 56279556

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection 1210.90 19.89 459 15677 24248 31656960
Cytomegalovirus viraemia 498.16 19.89 170 15966 6555 31674653
Drug resistance 472.76 19.89 233 15903 23220 31657988
Pathogen resistance 317.62 19.89 131 16005 8570 31672638
Pneumonia cytomegaloviral 230.61 19.89 77 16059 2767 31678441
Cytomegalovirus chorioretinitis 220.32 19.89 78 16058 3350 31677858
Cytomegalovirus infection reactivation 173.92 19.89 68 16068 3861 31677347
End stage renal disease 170.41 19.89 83 16053 8026 31673182
Cytomegalovirus colitis 162.71 19.89 58 16078 2540 31678668
Encephalitis cytomegalovirus 155.88 19.89 39 16097 483 31680725
Leukopenia 154.64 19.89 168 15968 57660 31623548
Pancytopenia 153.63 19.89 205 15931 87111 31594097
Cytomegalovirus test positive 137.35 19.89 56 16080 3549 31677659
Aspergillus infection 135.03 19.89 80 16056 11448 31669760
Transplant rejection 134.07 19.89 75 16061 9633 31671575
Graft versus host disease 131.60 19.89 76 16060 10371 31670837
Multiple organ dysfunction syndrome 127.42 19.89 165 15971 68038 31613170
Pneumocystis jirovecii pneumonia 121.59 19.89 89 16047 18162 31663046
Product use in unapproved indication 116.94 19.89 193 15943 98978 31582230
Bone marrow failure 111.23 19.89 101 16035 27907 31653301
Cystitis haemorrhagic 98.84 19.89 50 16086 5239 31675969
Fatigue 96.38 19.89 26 16110 335180 31346028
Respiratory failure 95.65 19.89 179 15957 101270 31579938
Off label use 95.19 19.89 388 15748 346886 31334322
Acute graft versus host disease 94.50 19.89 51 16085 6102 31675106
Post transplant lymphoproliferative disorder 89.53 19.89 49 16087 6027 31675181
Thrombotic microangiopathy 74.77 19.89 51 16085 9300 31671908
Kidney transplant rejection 71.10 19.89 45 16091 7237 31673971
Haemophagocytic lymphohistiocytosis 68.97 19.89 53 16083 11625 31669583
Incision site pain 68.18 19.89 28 16108 1806 31679402
Glomerulosclerosis 68.17 19.89 22 16114 708 31680500
Nephropathy toxic 68.09 19.89 52 16084 11301 31669907
Fall 67.19 19.89 8 16128 186081 31495127
Parvovirus B19 infection 66.90 19.89 22 16114 752 31680456
Chronic graft versus host disease 66.31 19.89 36 16100 4356 31676852
Dizziness 66.20 19.89 11 16125 199136 31482072
Encephalitis 58.87 19.89 39 16097 6776 31674432
Drug ineffective 58.60 19.89 372 15764 395201 31286007
Adenovirus infection 58.30 19.89 34 16102 4720 31676488
Epstein-Barr virus infection 58.16 19.89 39 16097 6914 31674294
Acute graft versus host disease in skin 57.78 19.89 34 16102 4798 31676410
Renal impairment 57.34 19.89 132 16004 86217 31594991
Acute graft versus host disease in intestine 56.51 19.89 27 16109 2499 31678709
Klebsiella infection 56.40 19.89 40 16096 7763 31673445
Neutropenia 56.27 19.89 178 15958 140186 31541022
Immune reconstitution inflammatory syndrome 52.46 19.89 39 16097 8139 31673069
Neutrophil Pelger-Huet anomaly present 52.05 19.89 14 16122 234 31680974
Cytomegalovirus syndrome 51.73 19.89 12 16124 105 31681103
BK virus infection 51.03 19.89 32 16104 5063 31676145
Aplastic anaemia 50.51 19.89 40 16096 9163 31672045
Cytomegalovirus gastrointestinal infection 50.28 19.89 13 16123 185 31681023
Product use issue 49.51 19.89 97 16039 56662 31624546
Septic shock 47.10 19.89 104 16032 66054 31615154
Necrotising retinitis 46.50 19.89 17 16119 800 31680408
Myelosuppression 46.31 19.89 47 16089 14873 31666335
Asthenia 45.84 19.89 29 16107 224726 31456482
Human herpesvirus 8 infection 45.50 19.89 17 16119 851 31680357
Candida infection 42.95 19.89 47 16089 16211 31664997
Death 42.70 19.89 74 16062 360495 31320713
Cytomegalovirus oesophagitis 42.50 19.89 14 16122 481 31680727
Epstein-Barr viraemia 42.47 19.89 17 16119 1026 31680182
Bronchopulmonary aspergillosis 42.41 19.89 43 16093 13591 31667617
Graft versus host disease in skin 42.20 19.89 25 16111 3572 31677636
Product dose omission issue 42.17 19.89 3 16133 105583 31575625
Viral load increased 41.79 19.89 21 16115 2168 31679040
Pain 41.04 19.89 22 16114 186737 31494471
Lymphocyte count decreased 40.11 19.89 51 16085 20598 31660610
Acanthamoeba infection 39.91 19.89 13 16123 431 31680777
Enterococcal infection 39.65 19.89 34 16102 8697 31672511
Cytomegalovirus gastritis 38.72 19.89 11 16125 227 31680981
Pneumocystis jirovecii infection 38.31 19.89 18 16118 1604 31679604
Aplasia pure red cell 38.23 19.89 28 16108 5709 31675499
Cytomegalovirus enterocolitis 37.86 19.89 15 16121 881 31680327
Macular fibrosis 37.82 19.89 12 16124 365 31680843
Botulism 37.59 19.89 10 16126 160 31681048
Nausea 37.53 19.89 62 16074 307885 31373323
Pseudomonas infection 37.37 19.89 37 16099 11364 31669844
Pyrexia 36.08 19.89 271 15865 303569 31377639
Brain herniation 36.02 19.89 23 16113 3754 31677454
Disseminated cytomegaloviral infection 35.12 19.89 10 16126 208 31681000
Pneumonia bacterial 34.84 19.89 34 16102 10262 31670946
Arthralgia 34.50 19.89 17 16119 151407 31529801
Red blood cells urine positive 34.29 19.89 17 16119 1705 31679503
Dyspnoea 33.38 19.89 79 16057 343400 31337808
Retinal scar 32.24 19.89 10 16126 282 31680926
Intentional product use issue 32.23 19.89 75 16061 49272 31631936
Myocardial infarction 32.10 19.89 9 16127 113445 31567763
Retinitis 31.84 19.89 10 16126 294 31680914
Pruritus 31.77 19.89 12 16124 125155 31556053
Kidney fibrosis 31.03 19.89 17 16119 2093 31679115
Headache 30.67 19.89 29 16107 183623 31497585
Epstein-Barr virus associated lymphoproliferative disorder 30.63 19.89 16 16120 1790 31679418
Renal tubular disorder 30.47 19.89 22 16114 4388 31676820
Retinal detachment 30.24 19.89 23 16113 4963 31676245
Pneumonia pseudomonal 30.01 19.89 20 16116 3509 31677699
Drug ineffective for unapproved indication 30.00 19.89 41 16095 17749 31663459
Toxoplasmosis 29.42 19.89 14 16122 1283 31679925
Epstein-Barr virus infection reactivation 28.47 19.89 12 16124 826 31680382
Scedosporium infection 28.04 19.89 12 16124 858 31680350
Malaise 27.68 19.89 27 16109 168484 31512724
Back pain 26.92 19.89 11 16125 109402 31571806
Adenoviral hepatitis 26.83 19.89 10 16126 497 31680711
Glomerulonephropathy 26.56 19.89 8 16128 204 31681004
Cytopenia 25.95 19.89 30 16106 10980 31670228
Infection reactivation 25.93 19.89 13 16123 1335 31679873
Meningoencephalitis herpetic 25.63 19.89 11 16125 792 31680416
Graft versus host disease in gastrointestinal tract 25.52 19.89 18 16118 3461 31677747
Red blood cell schistocytes present 25.51 19.89 8 16128 234 31680974
Fungal sepsis 25.34 19.89 11 16125 814 31680394
Oesophagopleural fistula 25.33 19.89 6 16130 58 31681150
Large intestinal ulcer 25.06 19.89 14 16122 1791 31679417
Septic embolus 25.04 19.89 12 16124 1117 31680091
Renal failure 24.68 19.89 126 16010 123204 31558004
Pharyngeal abscess 24.47 19.89 9 16127 431 31680777
Hyperhidrosis 24.03 19.89 3 16133 67390 31613818
Cerebral toxoplasmosis 24.01 19.89 13 16123 1564 31679644
Acute respiratory distress syndrome 23.92 19.89 44 16092 24496 31656712
Cytomegalovirus enteritis 23.87 19.89 9 16127 462 31680746
Pain in extremity 23.63 19.89 15 16121 116188 31565020
Flavobacterium infection 23.57 19.89 6 16130 80 31681128
Procedural pain 23.46 19.89 19 16117 4490 31676718
Brain compression 23.33 19.89 7 16129 176 31681032
ADAMTS13 activity decreased 23.23 19.89 6 16130 85 31681123
Blood pressure increased 23.11 19.89 6 16130 79627 31601581
Cardiac failure congestive 23.01 19.89 6 16130 79381 31601827
Depression 22.55 19.89 9 16127 90806 31590402
Eye infection fungal 22.37 19.89 8 16128 353 31680855
Lymphadenopathy mediastinal 22.22 19.89 14 16122 2232 31678976
Protein urine present 22.01 19.89 19 16117 4901 31676307
Scopulariopsis infection 22.00 19.89 6 16130 106 31681102
Viral mutation identified 21.89 19.89 15 16121 2754 31678454
Human herpesvirus 6 infection 21.39 19.89 13 16123 1944 31679264
Chimerism 21.38 19.89 7 16129 236 31680972
Cytomegalovirus hepatitis 21.19 19.89 8 16128 412 31680796
Malignant neoplasm progression 21.01 19.89 7 16129 78991 31602217
Bone marrow disorder 20.85 19.89 12 16124 1624 31679584
Fungal infection 20.80 19.89 31 16105 14520 31666688
Enterococcal bacteraemia 20.50 19.89 12 16124 1676 31679532
Diffuse alveolar damage 20.44 19.89 13 16123 2106 31679102
Cytomegalovirus duodenitis 20.28 19.89 5 16131 58 31681150
Syncope 20.25 19.89 9 16127 85173 31596035
Myocarditis toxoplasmal 20.20 19.89 5 16131 59 31681149
Drug interaction 20.17 19.89 48 16088 208495 31472713
Organising pneumonia 20.16 19.89 19 16117 5491 31675717
Malnutrition 20.16 19.89 27 16109 11466 31669742
Bacterial toxaemia 20.15 19.89 6 16130 147 31681061
Complications of transplanted kidney 20.03 19.89 17 16119 4288 31676920

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytomegalovirus infection 2196.58 19.27 739 24929 39019 70863757
Drug resistance 925.84 19.27 389 25279 37801 70864975
Cytomegalovirus viraemia 841.24 19.27 266 25402 11419 70891357
Pathogen resistance 604.05 19.27 214 25454 13065 70889711
Cytomegalovirus chorioretinitis 370.31 19.27 118 25550 5180 70897596
Encephalitis cytomegalovirus 369.51 19.27 84 25584 972 70901804
Post transplant lymphoproliferative disorder 354.14 19.27 136 25532 10409 70892367
Pneumonia cytomegaloviral 353.81 19.27 110 25558 4451 70898325
Cytomegalovirus infection reactivation 333.99 19.27 116 25552 6665 70896111
Multiple organ dysfunction syndrome 332.34 19.27 291 25377 108224 70794552
Epstein-Barr virus infection 307.90 19.27 131 25537 13067 70889709
Pancytopenia 301.43 19.27 320 25348 150787 70751989
Cytomegalovirus colitis 282.51 19.27 91 25577 4135 70898641
Cytomegalovirus test positive 262.70 19.27 92 25576 5416 70897360
Leukopenia 260.50 19.27 252 25416 106308 70796468
Graft versus host disease 247.76 19.27 117 25551 14906 70887870
Smooth muscle cell neoplasm 231.10 19.27 56 25612 869 70901907
Transplant rejection 218.02 19.27 114 25554 18057 70884719
Off label use 211.89 19.27 668 25000 742392 70160384
Product use in unapproved indication 198.64 19.27 305 25363 207173 70695603
Aspergillus infection 197.13 19.27 106 25562 17762 70885014
Cystitis haemorrhagic 196.13 19.27 84 25584 8509 70894267
Nephropathy toxic 190.83 19.27 105 25563 18409 70884367
Fatigue 187.54 19.27 36 25632 824283 70078493
End stage renal disease 169.23 19.27 82 25586 11051 70891725
Cytomegalovirus syndrome 167.17 19.27 35 25633 266 70902510
Bone marrow failure 163.15 19.27 138 25530 48872 70853904
Pneumocystis jirovecii pneumonia 162.50 19.27 113 25555 29969 70872807
Acute graft versus host disease 162.36 19.27 76 25592 9486 70893290
Haemophagocytic lymphohistiocytosis 153.52 19.27 93 25575 19519 70883257
Neutropenia 135.74 19.27 292 25376 256864 70645912
Pain 135.52 19.27 31 25637 628785 70273991
Renal impairment 133.95 19.27 209 25459 143728 70759048
Respiratory failure 119.69 19.27 217 25451 168518 70734258
Adenovirus infection 114.41 19.27 56 25612 7712 70895064
Septic shock 114.29 19.27 170 25498 112088 70790688
Thrombotic microangiopathy 113.00 19.27 74 25594 17774 70885002
BK virus infection 112.91 19.27 56 25612 7933 70894843
Parvovirus B19 infection 110.79 19.27 34 25634 1315 70901461
Arthralgia 110.01 19.27 24 25644 503366 70399410
Kidney transplant rejection 109.59 19.27 59 25609 9902 70892874
Cytomegalovirus gastrointestinal infection 104.90 19.27 26 25642 445 70902331
Nausea 101.22 19.27 96 25572 851992 70050784
Dizziness 97.68 19.27 24 25644 464117 70438659
Incision site pain 97.66 19.27 37 25631 2724 70900052
Cytomegalovirus enterocolitis 95.30 19.27 31 25637 1452 70901324
Epstein-Barr virus associated lymphoproliferative disorder 94.83 19.27 38 25630 3251 70899525
Graft versus host disease in skin 93.26 19.27 44 25624 5586 70897190
Fall 91.44 19.27 24 25644 444072 70458704
Chronic graft versus host disease 91.39 19.27 46 25622 6724 70896052
Cytomegalovirus oesophagitis 89.64 19.27 25 25643 687 70902089
Acute graft versus host disease in skin 89.09 19.27 46 25622 7091 70895685
Dyspnoea 88.80 19.27 89 25579 769971 70132805
Epstein-Barr viraemia 83.63 19.27 30 25638 1893 70900883
Klebsiella infection 82.62 19.27 56 25612 14236 70888540
Bronchopulmonary aspergillosis 82.17 19.27 65 25603 20937 70881839
Headache 81.81 19.27 55 25613 580350 70322426
Cytomegalovirus gastritis 81.17 19.27 21 25647 430 70902346
Immune reconstitution inflammatory syndrome 80.14 19.27 53 25615 12937 70889839
Aplasia pure red cell 79.23 19.27 43 25625 7331 70895445
Product use issue 75.68 19.27 187 25481 179750 70723026
Epstein-Barr virus infection reactivation 74.88 19.27 26 25642 1490 70901286
Drug ineffective 74.14 19.27 586 25082 939166 69963610
Myelosuppression 72.97 19.27 71 25597 30074 70872702
Necrotising retinitis 72.52 19.27 24 25644 1187 70901589
Enterococcal infection 72.29 19.27 52 25616 14530 70888246
Renal failure 71.74 19.27 189 25479 188881 70713895
Sepsis 71.02 19.27 222 25446 244323 70658453
Pruritus 70.47 19.27 19 25649 345541 70557235
Graft versus host disease in gastrointestinal tract 70.44 19.27 37 25631 5907 70896869
Transplant dysfunction 67.93 19.27 38 25630 6871 70895905
Pyrexia 66.89 19.27 411 25257 606541 70296235
Product dose omission issue 62.89 19.27 4 25664 217464 70685312
Pseudomonas infection 62.17 19.27 53 25615 18941 70883835
Aplastic anaemia 61.69 19.27 50 25618 16666 70886110
Peripheral swelling 61.20 19.27 7 25661 236556 70666220
Glomerulosclerosis 61.07 19.27 20 25648 957 70901819
Malaise 59.64 19.27 42 25626 432890 70469886
Encephalitis 59.58 19.27 45 25623 13540 70889236
Viral haemorrhagic cystitis 59.26 19.27 23 25645 1808 70900968
Anxiety 58.32 19.27 6 25662 220324 70682452
Disseminated cytomegaloviral infection 57.46 19.27 16 25652 437 70902339
Viral load increased 57.43 19.27 25 25643 2631 70900145
Pain in extremity 56.53 19.27 24 25644 328058 70574718
Red blood cells urine positive 54.91 19.27 29 25639 4680 70898096
Acute graft versus host disease in intestine 54.67 19.27 27 25641 3789 70898987
Abdominal discomfort 53.93 19.27 7 25661 214651 70688125
Intentional product use issue 53.83 19.27 128 25540 120014 70782762
Asthenia 53.64 19.27 52 25616 457614 70445162
Alopecia 53.59 19.27 5 25663 198485 70704291
Back pain 53.24 19.27 16 25652 271136 70631640
Candida infection 53.18 19.27 64 25604 34409 70868367
Neutrophil Pelger-Huet anomaly present 51.77 19.27 14 25654 342 70902434
Lymphocyte count decreased 51.70 19.27 71 25597 43468 70859308
Complications of transplanted kidney 51.27 19.27 30 25638 5904 70896872
Human herpesvirus 8 infection 51.03 19.27 18 25650 1081 70901695
Drug intolerance 50.77 19.27 10 25658 225677 70677099
Swelling 50.24 19.27 5 25663 188534 70714242
Mucormycosis 50.17 19.27 33 25635 7981 70894795
Hypogammaglobulinaemia 50.12 19.27 38 25630 11500 70891276
Cytomegalovirus enteritis 49.63 19.27 16 25652 728 70902048
Brain herniation 49.37 19.27 31 25637 6925 70895851
Gait disturbance 49.09 19.27 5 25663 185101 70717675
Human herpesvirus 6 infection 48.52 19.27 27 25641 4832 70897944
Vomiting 48.49 19.27 88 25580 593023 70309753
Liver transplant rejection 47.80 19.27 23 25645 3049 70899727
Acute respiratory distress syndrome 47.08 19.27 66 25602 41188 70861588
Pneumonia pseudomonal 46.59 19.27 27 25641 5219 70897557
Acanthamoeba infection 46.03 19.27 14 25654 525 70902251
Cytomegalovirus hepatitis 45.70 19.27 15 25653 723 70902053
Blood pressure increased 45.36 19.27 7 25661 188510 70714266
Haemorrhage intracranial 44.93 19.27 50 25618 24727 70878049
Weight increased 44.58 19.27 16 25652 242315 70660461
Nasopharyngitis 43.81 19.27 13 25655 222193 70680583
Pneumonia bacterial 41.78 19.27 40 25628 16601 70886175
Urticaria 41.72 19.27 5 25663 163044 70739732
Polyomavirus-associated nephropathy 41.63 19.27 25 25643 5158 70897618
Retinal detachment 41.52 19.27 30 25638 8437 70894339
Muscle spasms 41.26 19.27 4 25664 154042 70748734
Ureaplasma infection 41.08 19.27 14 25654 758 70902018
Immunosuppressant drug level increased 41.04 19.27 29 25639 7878 70894898
Drug hypersensitivity 40.91 19.27 22 25646 262437 70640339
Hypersensitivity 40.88 19.27 16 25652 229796 70672980
Thrombocytopenia 40.03 19.27 182 25486 238928 70663848
Scedosporium infection 39.71 19.27 16 25652 1388 70901388
Bacterial sepsis 39.58 19.27 28 25640 7619 70895157
Pneumocystis jirovecii infection 39.09 19.27 19 25649 2575 70900201
Hepatic function abnormal 38.99 19.27 80 25588 67916 70834860
Cytopenia 38.58 19.27 39 25629 17284 70885492
Pulmonary haemorrhage 38.44 19.27 35 25633 13638 70889138
Therapeutic product effect decreased 37.56 19.27 4 25664 143014 70759762
Respiratory distress 37.05 19.27 69 25599 54581 70848195
Cerebral toxoplasmosis 36.75 19.27 17 25651 2063 70900713
Lung transplant rejection 36.54 19.27 15 25653 1365 70901411
Gastric ulcer 36.48 19.27 51 25617 31739 70871037
Viral mutation identified 35.82 19.27 20 25648 3602 70899174
Contusion 35.16 19.27 3 25665 128033 70774743
Rash 34.75 19.27 84 25584 510478 70392298
Drug ineffective for unapproved indication 34.45 19.27 55 25613 38483 70864293
Protein urine present 34.33 19.27 28 25640 9412 70893364
Insomnia 34.31 19.27 18 25650 217788 70684988
Macular fibrosis 34.21 19.27 12 25656 709 70902067
Myocardial infarction 33.91 19.27 10 25658 171635 70731141
Abdominal pain upper 33.58 19.27 14 25654 193588 70709188
Depression 33.54 19.27 15 25653 198959 70703817
Renal tubular disorder 33.09 19.27 23 25645 6087 70896689
Botulism 33.08 19.27 10 25658 367 70902409
Strongyloidiasis 32.63 19.27 19 25649 3704 70899072
Retinal scar 32.38 19.27 10 25658 395 70902381
Death 32.33 19.27 87 25581 509974 70392802
Musculoskeletal stiffness 32.28 19.27 7 25661 147753 70755023
Somnolence 32.25 19.27 19 25649 215587 70687189
Hepatic failure 32.10 19.27 67 25601 57558 70845218
Kidney fibrosis 32.03 19.27 18 25650 3282 70899494
Injection site pain 31.64 19.27 3 25665 117616 70785160
Fungal infection 31.49 19.27 52 25616 37415 70865361
Disseminated intravascular coagulation 31.48 19.27 49 25619 33549 70869227
Sinusitis 31.39 19.27 11 25657 169184 70733592
Hyperhidrosis 31.39 19.27 5 25663 131581 70771195
Complications of transplanted lung 31.28 19.27 10 25658 443 70902333
Viraemia 30.92 19.27 16 25652 2476 70900300
Transplant failure 30.91 19.27 19 25649 4088 70898688
Posterior reversible encephalopathy syndrome 30.80 19.27 41 25627 24361 70878415
Neutrophil count increased 30.76 19.27 43 25625 26752 70876024
Cytomegalovirus duodenitis 30.63 19.27 7 25661 83 70902693
Cardiac failure congestive 30.45 19.27 6 25662 135451 70767325
Syncope 30.36 19.27 11 25657 165698 70737078
Constipation 30.32 19.27 28 25640 252410 70650366
Asthma 30.18 19.27 4 25664 120789 70781987
Lower respiratory tract infection 29.72 19.27 3 25665 111910 70790866
Infection reactivation 28.77 19.27 15 25653 2358 70900418
Infusion related reaction 28.72 19.27 18 25650 197516 70705260
Lymphoproliferative disorder 28.72 19.27 20 25648 5309 70897467
Blood urea increased 28.69 19.27 56 25612 45853 70856923
Complications of transplanted liver 28.38 19.27 9 25659 388 70902388
Neurological decompensation 28.36 19.27 19 25649 4737 70898039
Contraindicated product administered 28.17 19.27 7 25661 134605 70768171
Chest pain 27.73 19.27 30 25638 251230 70651546
Agranulocytosis 27.46 19.27 51 25617 40247 70862529
Toxoplasmosis 27.43 19.27 15 25653 2595 70900181
Fungal sepsis 27.26 19.27 13 25655 1690 70901086
Squamous cell carcinoma of skin 27.18 19.27 28 25640 12684 70890092
Lymphopenia 27.18 19.27 41 25627 27318 70875458
Organising pneumonia 26.84 19.27 25 25643 10025 70892751
Enterococcal bacteraemia 26.82 19.27 15 25653 2711 70900065
Meningoencephalitis herpetic 26.31 19.27 13 25655 1826 70900950
Myalgia 26.25 19.27 14 25654 167878 70734898
Septic embolus 26.17 19.27 13 25655 1847 70900929
Glomerulonephropathy 25.95 19.27 8 25660 314 70902462
Toxic epidermal necrolysis 25.63 19.27 49 25619 39508 70863268
Cerebrovascular accident 25.48 19.27 10 25658 143460 70759316
Hypoproteinaemia 25.33 19.27 16 25652 3610 70899166
Pleural effusion 25.16 19.27 105 25563 132759 70770017
Systemic mycosis 25.14 19.27 14 25654 2508 70900268
Escherichia sepsis 24.58 19.27 21 25647 7522 70895254
Flavobacterium infection 24.53 19.27 6 25662 97 70902679
Malnutrition 23.91 19.27 33 25635 20284 70882492
Pharyngeal abscess 23.82 19.27 9 25659 657 70902119
Wheezing 23.81 19.27 3 25665 94167 70808609
Venoocclusive liver disease 23.70 19.27 24 25644 10654 70892122
Scopulariopsis infection 23.42 19.27 6 25662 118 70902658
Actinic keratosis 23.37 19.27 18 25650 5572 70897204
Ophthalmic herpes simplex 23.15 19.27 9 25659 710 70902066
Platelet count decreased 22.95 19.27 126 25542 178096 70724680
Balance disorder 22.48 19.27 3 25665 90125 70812651
Chimerism 22.46 19.27 7 25661 285 70902491
Oesophagopleural fistula 22.39 19.27 5 25663 53 70902723
Focal segmental glomerulosclerosis 22.04 19.27 14 25654 3190 70899586
Bacterial toxaemia 21.79 19.27 6 25662 157 70902619
Adenoviral hepatitis 21.75 19.27 9 25659 836 70901940
ADAMTS13 activity decreased 21.54 19.27 6 25662 164 70902612
Idiopathic pneumonia syndrome 21.54 19.27 8 25660 557 70902219
Loss of consciousness 21.53 19.27 15 25653 155701 70747075
Myocarditis toxoplasmal 21.52 19.27 5 25663 64 70902712
Opportunistic infection 21.47 19.27 13 25655 2723 70900053
Tubulointerstitial nephritis 21.47 19.27 41 25627 33035 70869741
Rhegmatogenous retinal detachment 21.44 19.27 6 25662 167 70902609
Diffuse alveolar damage 21.42 19.27 14 25654 3349 70899427
Encephalitis Japanese B 21.18 19.27 5 25663 69 70902707
Hypoaesthesia 21.01 19.27 15 25653 153724 70749052
Cerebral aspergillosis 21.00 19.27 11 25657 1745 70901031
Hypoalbuminaemia 20.93 19.27 30 25638 19092 70883684
Renal transplant failure 20.93 19.27 11 25657 1757 70901019
Acute graft versus host disease in liver 20.79 19.27 11 25657 1781 70900995
Meningitis viral 20.77 19.27 11 25657 1785 70900991
Hyperlactacidaemia 20.48 19.27 16 25652 5056 70897720
Haematotoxicity 20.45 19.27 25 25643 13649 70889127
Mobility decreased 20.33 19.27 6 25662 102993 70799783
Engraft failure 20.28 19.27 8 25660 656 70902120
Retinal haemorrhage 20.24 19.27 19 25649 7691 70895085
Macular oedema 20.24 19.27 16 25652 5146 70897630
Paraesthesia 20.15 19.27 14 25654 145523 70757253
Tractional retinal detachment 20.15 19.27 5 25663 86 70902690
Oliguria 20.10 19.27 26 25642 15025 70887751
Epstein-Barr virus test positive 19.92 19.27 9 25659 1034 70901742
Hydrocephalus 19.48 19.27 19 25649 8066 70894710
Varicella zoster oesophagitis 19.39 19.27 4 25664 28 70902748

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AB06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
ATC S01AD09 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antivirals
FDA MoA N0000020060 DNA Polymerase Inhibitors
FDA EXT N0000175459 Nucleoside Analog
FDA EPC N0000175461 Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor
FDA EPC N0000175466 Nucleoside Analog Antiviral
CHEBI has role CHEBI:35441 antiinfective agents
CHEBI has role CHEBI:36044 antiviral drugs
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cytomegaloviral retinitis indication 22455005
Herpes simplex dendritic keratitis indication 29943008
Paroxysmal supraventricular tachycardia indication 67198005
CMV Retinitis in AIDS Patients indication
Prevention of CMV Disease After Kidney-Pancreas Transplantation indication
CMV Retinitis in Immunocompromised Patients indication
Prevention of CMV Disease After Organ Transplant indication
Prevention of CMV Disease After Kidney Transplantation indication
Myocardial Perfusion Imaging Adjunct indication
Prevention of CMV Disease in Advanced HIV Patients indication
Prevention of CMV Disease After Cardiac Transplantation indication
Supraventricular tachycardia off-label use 6456007
Cytomegalovirus infection off-label use 28944009
CMV-Related Polyradiculopathy in AIDS Patients off-label use
Prevention of Cytomegalovirus Disease off-label use
Endophthalmitis contraindication 1847009 DOID:4692
Pericarditis contraindication 3238004 DOID:1787
Reduced visual acuity contraindication 13164000
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Disorder of autonomic nervous system contraindication 15241006
Complete atrioventricular block contraindication 27885002
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Vitreous hemorrhage contraindication 31341008
Transplantation of heart contraindication 32413006
Dehydration contraindication 34095006
Sick sinus syndrome contraindication 36083008 DOID:13884
Retinal detachment contraindication 42059000 DOID:5327
Low blood pressure contraindication 45007003
Acute nephropathy contraindication 58574008
Aortic valve stenosis contraindication 60573004 DOID:1712
Left to right cardiovascular shunt contraindication 66130006
Mitral valve stenosis contraindication 79619009 DOID:1754
Pulmonary emphysema contraindication 87433001
Kidney disease contraindication 90708001 DOID:557
Bilateral cataracts contraindication 95722004
Respiratory alkalosis contraindication 111378004
Eye infection contraindication 128351009
Uveitis contraindication 128473001 DOID:13141
Second degree atrioventricular block contraindication 195042002
Asthma contraindication 195967001 DOID:2841
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Aplastic anemia contraindication 306058006 DOID:12449
Left main coronary artery disease contraindication 371804009
Acute coronary syndrome contraindication 394659003
Respiratory insufficiency contraindication 409623005
Breastfeeding (mother) contraindication 413712001
Granulocytopenic disorder contraindication 417672002
Severe Bone Marrow Depression contraindication
Syncope due to Bradycardia contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.97 acidic
pKa2 12.38 acidic
pKa3 12.98 acidic
pKa4 3.68 Basic
pKa5 2.12 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Metabotropic glutamate receptor 1 GPCR Ki 6.05 WOMBAT-PK
Metabotropic glutamate receptor 5 GPCR Ki 5.41 WOMBAT-PK
DNA polymerase catalytic subunit Enzyme INHIBITOR WOMBAT-PK CHEMBL
Thymidine kinase Kinase WOMBAT-PK
Capsid scaffolding protein Enzyme EC50 6.07 WOMBAT-PK
Purine nucleoside phosphorylase Enzyme Kd 4.80 CHEMBL

External reference:

IDSource
4019764 VUID
N0000147855 NUI
D00333 KEGG_DRUG
107910-75-8 SECONDARY_CAS_RN
4019457 VANDF
4019764 VANDF
C0017066 UMLSCUI
CHEBI:465284 CHEBI
GA2 PDB_CHEM_ID
CHEMBL1200850 ChEMBL_ID
CHEMBL182 ChEMBL_ID
DB01004 DRUGBANK_ID
D015774 MESH_DESCRIPTOR_UI
135398740 PUBCHEM_CID
6023 INN_ID
P9G3CKZ4P5 UNII
4678 RXNORM
177021 MMSL
33722 MMSL
34097 MMSL
47373 MMSL
4775 MMSL
4776 MMSL
d00066 MMSL
003444 NDDF
003445 NDDF
372848001 SNOMEDCT_US
76587005 SNOMEDCT_US
78025001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 0143-9299 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 29 sections
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 14335-030 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENTRICULAR ANDA 30 sections
ZIRGAN HUMAN PRESCRIPTION DRUG LABEL 1 24208-535 GEL 1.50 mg OPHTHALMIC NDA 22 sections
ZIRGAN HUMAN PRESCRIPTION DRUG LABEL 1 24208-535 GEL 1.50 mg OPHTHALMIC NDA 22 sections
ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 25021-185 INJECTION, SOLUTION 50 mg INTRAVENOUS ANDA 28 sections
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 42023-173 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 29 sections
GANCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 51754-2500 INJECTION, SOLUTION 2 mg INTRAVENOUS NDA 18 sections
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 51817-171 INJECTION, SOLUTION 500 mg INTRAVENOUS ANDA 29 sections
CytoveneIV HUMAN PRESCRIPTION DRUG LABEL 1 61269-450 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS NDA 31 sections
GANCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 63304-636 CAPSULE 250 mg ORAL ANDA 23 sections
GANCICLOVIR HUMAN PRESCRIPTION DRUG LABEL 1 63304-637 CAPSULE 500 mg ORAL ANDA 23 sections
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 63323-315 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 29 sections
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 63323-315 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 29 sections
Ganciclovir HUMAN PRESCRIPTION DRUG LABEL 1 70436-089 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENTRICULAR ANDA 29 sections